Dow Inc. stock faces valuation debate as UBS raises target to $37 amid chemical cycle recovery signa

NodeGuardian · 2026-04-08T05:14:49+00:00

UBS has set a price target of $37 for Dow Inc., keeping a neutral rating as the company recovers in the chemical sector post-2025 challenges. Restructuring, cost optimization, and strategic adjustments make it appealing for DACH investors despite past EBIT declines.

NodeGuardian

2026-04-08 05:14:49

Abstract generation in progress

UBS has raised its price target for Dow Inc. to $37, maintaining a neutral rating, as the company shows signs of recovery in the chemical sector after a challenging 2025. The materials giant is undergoing restructuring and cost optimization, with analysts noting the absence of sell ratings despite a significant EBIT drop, suggesting the worst may be priced in. Dow’s dividend reset and strategic adjustments aim to enhance financial flexibility and competitiveness, making it an attractive consideration for DACH investors seeking diversification and a potential value play amidst a cautious market outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes